IQVIA Holdings analyst views shift, shares trade below recent targets
22.06.2026 - 15:58:52 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 15:50.
IQVIA Holdings (US46266C1053) currently sits in the crosshairs of several major research houses. The NYSE-listed healthcare data specialist trades around 168 dollars, while Wall Street 12-month targets cluster significantly higher according to recent analyst compilations.
What recent analysts are saying
Morgan Stanley downgraded IQVIA Holdings from Overweight to Equal-Weight on 17 June 2026 after a period of robust share performance in the contract research and healthcare analytics space, as summarized by MarketScreener. The move contrasted with earlier positive views from TD Cowen, which reiterated a Buy rating on 8 June 2026.
On 18 June 2026 Rothschild & Co Redburn reiterated its Buy recommendation on IQVIA, underscoring that many European and US houses still see upside in the stock despite the Morgan Stanley shift. Aggregated data from Bitget indicates an average 12?month target price of around 284 dollars, more than 60 percent above the latest quoted level.
How the consensus stacks up
According to Bitget’s compilation of Wall Street estimates, IQVIA Holdings shares have a consensus target of 284.05 dollars, with a high estimate of 340.68 dollars and a low of 198.27 dollars over the next 12 months. This places the stock well within the broader US healthcare services universe alongside peers such as Thermo Fisher Scientific and IQVIA’s contract research rivals.
Bitget also reports that IQVIA shares last closed at 167.77 dollars, marking a 1.70 percent decline on the day of that snapshot. In a recent market note, MarketBeat quoted a fair?value indication of 168.82 dollars in early NYSE trading, highlighting that the market price remains well below the mid?200 dollar range implied by many targets.
All news and analysis on the IQVIA Holdings shares
Further headlines, background pieces and quote data on IQVIA Holdings can be found in the dedicated topic overview on ad-hoc-news.de and on the company’s Investor Relations page.
How IQVIA earns its money
IQVIA Holdings generates most of its revenue from advanced clinical research services and healthcare data analytics for pharmaceutical companies, biotech firms and healthcare providers. The group combines real?world data, technology platforms and contract research capabilities to support drug development and commercial decision?making.
Where the shares trade today
The IQVIA Holdings shares (US46266C1053) most recently traded on the NYSE at 167.77 US dollars, based on the latest price snapshot reported by Bitget for the last trading day.
Key data on the IQVIA Holdings shares
- Company: IQVIA Holdings Inc.
- ISIN: US46266C1053
- WKN: A2JSPM
- Ticker: IQV
- Trading venue: NYSE
- Price (as of 2026-06-21, 22:00): 167.77 USD
- Market cap: 30.0 billion USD (as of 2026-06-21)
- Sector / industry: Healthcare technology and contract research services
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
